
Global report - September 4, 2017
Pfizer’s patent criticized
The pharma giant was recently granted a patent on their vaccine for pneumonia in India, which has been highly questioned by for example Medecins sans Frontiers (MSF). The patent approval means that other pharma companies are not allowed to manufacture cheaper versions of the vaccine and this is a major backlash in the fight for […]

Drug Development Pharma - August 13, 2015
New vaccine against Ebola virus
The Research Council of Norway’s Programme for Global Health and Vaccination Research (GLOBVAC) is co-funding testing of a new vaccine against Ebola. Preliminary results from the Norwegian-led trial underway in Guinea, published in the medical journal The Lancet, indicate that the vaccine may provide complete protection against Ebola virus disease. The vaccine study is a […]

Drug Development Pharma - November 14, 2014
New Dengue Vaccine Sought
Norwegian researchers are hoping to develop a plant-based vaccine for dengue fever, an often deadly disease on the rise in Asia. As was the case with the ZMapp Ebola medicine, the scientists are utilizing tobacco plants to develop antibodies. Developing new vaccines often is extremely costly and time-consuming, so researchers are eager to find easier […]

Clinical Trials - November 4, 2014
Ebola Nasal Vaccine Trials
Researchers at the University of Texas at Austin have a nasal vaccine for the Ebola virus in development that has provided long-term protection for non-human primates against the virus. Small pre-clinical study results are the first to show that a single dose of a non-injectable vaccine for Ebola could have a longer duration. The research […]

Clinical Trials - October 29, 2014
New study planned for Diamyd’s diabetes vaccine
In order to increase the scientific value of the research on preventative treatment with the Diamyd® diabetes vaccine, the research team at Lund University, who have been driving the DiAPREV-IT study since 2009, decided to expand the dataset with additional children at high risk of presenting with type 1 diabetes. Therefore, after discussions with the […]

Collaboration - December 11, 2013
Lundbeck and Otsuka to develop investigational vaccine candidate
H. Lundbeck and Otsuka Pharmaceutical today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer’s disease. Lu AF20513 is an anti-Aβ active vaccine candidate for Alzheimer’s disease which currently is in preclinical development. It is designed towards an optimal immunogenic response in the elderly, […]